×
For best experience we recommend to activate Javascript in your browser.
Recombinant CALCRL (Erenumab Biosimilar) antibody
The Human Monoclonal anti-CALCRL (Erenumab Biosimilar) antibody (ABIN7675836) specifically detects CALCRL (Erenumab Biosimilar) in ELISA, FACS, BLI, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7675836
$346.15
Plus shipping costs $50.00
1 mg ABIN7581269
100 μg ABIN7675836
1 mg ABIN7581269
100 μg ABIN7675836
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant CALCRL (Erenumab Biosimilar) antibody (ABIN7675836)
Target
CALCRL (Erenumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for CALCRL (Erenumab Biosimilar) antibodies
Human
Clonality
All clonalities for CALCRL (Erenumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for CALCRL (Erenumab Biosimilar) antibodies
This CALCRL (Erenumab Biosimilar) antibody is un-conjugated
Application
ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-CALCRL (Erenumab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-CALCRL / CGRPR Reference Antibody (erenumab)
Characteristics
Anti-CALCRL / CGRPR Reference Antibody (erenumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG2
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for CALCRL (Erenumab Biosimilar)
(hide)
Target
CALCRL (Erenumab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q16602
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-CALCRL (Erenumab Biosimilar) antibody (ABIN7675836)
Chat with us , powered by LiveChat